Last updated: February 17, 2026
Overview
NDC 67457-0217 corresponds to Tepezza (teprotumumab-trbw), a monoclonal antibody developed by Horizon Therapeutics for the treatment of Thyroid Eye Disease (TED). Approved by the FDA in January 2020, Tepezza has become the primary pharmaceutical treatment for TED, with its market growth driven by increasing diagnosis rates and limited alternatives.
Market Size and Growth Drivers
-
Prevalence: TED affects approximately 0.02% to 0.03% of the population, with higher rates among patients with Graves' disease. The global population with Graves' disease is estimated at 2.5 million, suggesting a TED patient base of roughly 500,000 to 750,000.
-
Diagnosis Rate: Historically, only 50-70% of TED cases are diagnosed early, delaying treatment. Increased awareness and improved diagnostic criteria have expanded the diagnosed population.
-
Treatment Landscape: Prior to Tepezza, treatment options were limited to corticosteroids, radiation, and surgical interventions, with no FDA-approved pharmacological options. Tepezza's approval shifted the paradigm, making it a first-line therapy.
-
Market Penetration: As of 2023, Tepezza has captured approximately 60% of newly diagnosed TED cases, with sales expanding as the drug gains acceptance among healthcare providers.
Revenue and Market Penetration Trends
-
Initial Launch: In 2020, Tepezza generated approximately $238 million globally, primarily in the U.S.
-
Growth Pattern: Sales increased to over $1.5 billion in 2022, reflecting increased prescriptions, expanded insurance coverage, and higher awareness.
-
Market Penetration: Estimated that by 2023, around 70% of eligible patients receive the drug, given the disease’s severity and limited alternatives.
Pricing Strategy and Reimbursement
-
List Price: The wholesale acquisition cost (WAC) for Tepezza is approximately $14,000 per infusion session; treatment involves 8 infusions over 24 weeks. This totals roughly $112,000 per patient.
-
Average Selling Price: Insurance reimbursements reduce the effective cost to payers, with net prices estimated around $80,000 to $100,000 per treatment course.
-
Reimbursement: Coverage rates are high (>90%) in the U.S., facilitated by FDA approval and CMS policies, supporting strong revenue trajectories.
Competitive Landscape
- No direct FDA-approved competitors exist, but off-label corticosteroid use persists.
- Clinical trials for similar indications (e.g., other autoimmune diseases) are underway, but no near-term alternative poses significant threat.
- Biosimilars are unlikely within the next 5-7 years because of patent protections and the complexity of monoclonal antibodies.
Price Projections (2023-2028)
| Year |
Estimated Global Sales |
Assumption |
Comments |
| 2023 |
$1.8 billion |
Currency stability, high market penetration, continued approval |
Reflects continued adoption and updated treatment guidelines |
| 2024 |
$2.2 billion |
Slight market expansion, increased awareness, new insurers coverage |
Potential increase in diagnosed and treated patients |
| 2025 |
$2.6 billion |
Market saturation approaches, minimal new competitors |
Typically, sales plateau as market matures |
| 2026 |
$3.0 billion |
Expanded indications or off-label uses, pricing adjustments |
Price increases may be limited by payer negotiations |
| 2027 |
$3.2 billion |
Regulatory submission for expanded use in other autoimmune indications |
Slight growth due to broader use |
| 2028 |
$3.4 billion |
Market stabilization, price adjustments to maintain volume |
Marginal growth, stable revenue base |
Factors Influencing Future Price and Market Size
- Regulatory Approvals: Positive outcomes in clinical trials for other autoimmune diseases could expand indications, increasing demand.
- Pricing Policies: Payer negotiations and potential value-based agreements could lower net prices.
- Market Access: Countries outside the U.S. with emerging awareness could see adoption, though pricing flexibility varies globally.
- Patent and Exclusivity: Patent expiry, expected around 2029, could introduce biosimilar competition, pressuring prices.
Risks and Uncertainties
- Regulatory developments in other markets may impact pricing strategies.
- Off-label competition or emerging therapies could compress market share.
- Insurance reimbursement policies may tighten, reducing net prices.
- Market saturation may lead to stagnating revenues beyond 2025.
Key Takeaways
- Tepezza is the predominant treatment for TED, with a growing market driven by increased diagnosis and accepted clinical practice.
- The drug’s price per treatment course averages $80,000 to $100,000, with net sales reaching approximately $2 billion in 2023.
- Market size is projected to grow at a compounded rate of approximately 15-20% annually through 2026, then plateauing as the market matures.
- Price stability is expected until patent expiry, after which biosimilar competition may significantly reduce prices.
- Future growth hinges on expanding indications, reimbursement dynamics, and market access outside the U.S.
FAQs
1. What are the primary drivers of Tepezza's revenue growth?
Increase in diagnosis rates, insurance coverage, clinician acceptance, and lack of direct competitors.
2. How does the price of Tepezza compare internationally?
International prices vary due to healthcare policies; generally, U.S. prices are higher, ranging from $80,000 to $112,000 per treatment course.
3. When is patent expiry likely, and how will it impact the market?
Patent protection is expected around 2029, after which biosimilar competitors may reduce prices significantly.
4. What are the key risks to the market projection?
Emergence of new therapies, regulatory changes, reimbursement restrictions, and slower-than-expected market adoption.
5. Are there emerging drugs that could replace Tepezza?
Currently, no approved alternatives exist. Clinical trials for related autoimmune conditions are ongoing but unlikely to impact the TED market before late 2020s.
References
- Horizon Therapeutics. (2023). Tepezza U.S. Sales Data.
- FDA. (2020). Approval of Tepezza for Thyroid Eye Disease.
- CNBC. (2022). Biotech Price Trends.
- IQVIA. (2023). Global Pharmaceutical Market Reports.
- CMS. (2023). Reimbursement Policies for Biologics.
